HeXun Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	112.31	147.22	33.49	-5.19	-42.99
Depreciation & Amortization	26.61	23.52	19.1	14.19	11.43
Other Amortization	1.2	1.2	1.2	0.53	0.48
Loss (Gain) From Sale of Assets	1.62	0.01	0.05	-0.02	-0.2
Stock-Based Compensation	2.77	-	-	0.3	-
Other Operating Activities	0.65	13.97	-0.07	-0.05	0.47
Change in Accounts Receivable	25.91	-62.39	-17.3	-4.98	-
Change in Inventory	5.91	-10.98	-4.6	-	-
Change in Accounts Payable	-5.07	1.81	-0.8	0.42	-4.3
Change in Unearned Revenue	8.67	6.97	-3.37	5.1	-
Change in Other Net Operating Assets	-3	-0.4	15.39	0.93	-0.39
Operating Cash Flow	177.56	120.92	43.09	11.23	-35.5
Operating Cash Flow Growth	60.07%	180.62%	283.77%	-	-
Capital Expenditures	-21.34	-37.29	-20.67	-1.23	-
Sale of Property, Plant & Equipment	-	-	-	0.13	8.84
Sale (Purchase) of Intangibles	-0.33	-	-0.64	-5.96	-
Investment in Securities	-109.13	-100	-	-72	-
Other Investing Activities	-0.09	-	-3.97	-	-35.78
Investing Cash Flow	-130.9	-137.29	-25.28	-79.05	-26.95
Long-Term Debt Repaid	-	-40.31	-4.88	-2.46	-2.01
Net Debt Issued (Repaid)	-3.59	-40.31	-4.88	-2.46	-2.01
Issuance of Common Stock	-	-	125	105	78
Other Financing Activities	5.5	-	-	-	-0.2
Financing Cash Flow	1.91	-40.31	120.12	102.54	75.79
Net Cash Flow	48.57	-56.68	137.93	34.72	13.34
Free Cash Flow	156.22	83.63	22.42	10	-35.5
Free Cash Flow Growth	123.67%	272.98%	124.19%	-	-
Free Cash Flow Margin	53.71%	29.20%	17.17%	20.22%	-
Free Cash Flow Per Share	3.39	1.82	0.49	0.27	-1.16
Cash Interest Paid	1.11	1.24	1.79	1.64	1.57
Levered Free Cash Flow	-	33.7	9.68	0.46	-
Unlevered Free Cash Flow	-	34.43	10.84	1.48	-
Change in Working Capital	32.41	-64.99	-10.68	1.47	-4.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.